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Abstract: Invasive aspergillosis (IA) is a severe complication among hematopoietic stem cell
transplant recipients or patients with hematological malignancies and neutropenia following
anti-cancer therapy. Moreover, IA is increasingly observed in other populations, such as solid-organ
transplant recipients, patients with solid tumors or auto-immune diseases, and among intensive care
unit patients. Frequent delay in diagnosis is associated with high mortality rates. Cultures from
clinical specimens remain sterile in many cases and the diagnosis of IA often only relies on non-specific
radiological signs in the presence of host risk factors. Tests for detection of galactomannan- (GM)
and 1,3-β-D-glucan (BDG) are useful adjunctive tools for the early diagnosis of IA and may have
a role in monitoring response to therapy. However, the sensitivity and specificity of these fungal
biomarkers are not optimal and variations between patient populations are observed. This review
discusses the role and interpretation of GM and BDG testing for the diagnosis of IA in different
clinical samples (serum, bronchoalveolar lavage fluid, cerebrospinal fluid) and different groups of
patients (onco-hematological patients, solid-organ transplant recipients, other patients at risk of IA).
Keywords: Aspergillus fumigatus; invasive aspergillosis; fungal biomarkers; galactomannan;
1,3-β-D-glucan
1. Introduction
Invasive aspergillosis (IA) represents a major threat in patients with depressed immune system.
Patients with hematologic malignancies and chemotherapy-induced neutropenia or hematopoietic
stem cell transplantation (HSCT) are at highest risk [1]. However, IA is increasingly observed in
patients populations with diverse types of underlying diseases and level of immunosuppression, such
as solid-organ transplant recipients, patients with solid tumors, auto-immune disorders, congenital
immunodeficiency or chronic pulmonary diseases [2,3]. The pathogenesis and clinical presentation of
IA may differ in these settings with various degrees of invasiveness.
Diagnosis of IA remains difficult because of the lack of sensitivity of conventional culture methods.
Therefore, non culture-based methods, such as detection of DNA by PCR or measurements of fungal
biomarkers in blood or respiratory samples, are important adjunctive tools. The galactomannan (GM)
and 1,3-β-D-glucan (BDG) assays have been included as microbiological criteria in the definitions
of invasive fungal infections by the European Organization for Research and Treatment of Cancer
(EORTC) and the Mycoses Study Group (MSG) [4]. However, the role and interpretation of these tests
for the diagnosis of IA in various populations and clinical settings is still debated because of their
limited sensitivity and specificity.
The objective of this review is to provide an overview of the current evidence of the performance
of these tests and to discuss their role and interpretation in diverse patients populations.
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2. The Tests
Characteristics of GM and BDG assays are summarized in Table 1. The test currently used
for GM detection is the Platelia Aspergillus EIA (Bio-Rad Laboratories, Marne-La-Coquette, France).
This enzyme immunoassay uses the rat monoclonal antibody EBA-2 directed against Aspergillus
galactomannan. The antigen is first bound in the wells of the microplate coated with the EBA-2 antibody
and then revealed by binding to the peroxidase-linked EBA-2 antibody resulting in a colorimetric
reaction after addition of the substrate. The optical density (OD) is measured and expressed as a
ratio of a control sample. Albeit specific for the detection of Aspergillus spp., the test may exhibit
cross-reactions with other fungi, in particular those of the family Trichocomaceae (e.g., Penicillium spp.,
Paecilomyces spp.), Fusarium spp. and Histoplasma capsulatum. The Platelia Aspergillus EIA is validated
for use in both serum and bronchoalveolar lavage (BAL) fluid samples. Testing in cerebrospinal
fluid (CSF) may be considered for the diagnosis of cerebral aspergillosis on the basis of experts
opinions [4,5]. The cut-off of positivity was initially set up at an OD of 1.5 and subsequently lowered
at 0.5 by the manufacturer. The EORTC-MSG panel included a positive GM value as a microbiological
criterion of invasive fungal infection (IFI), without specifying a threshold to define a positive result [4].
The European Conference on Infections in Leukemia (ECIL) laboratory working group recommended
to consider a single value ě0.7 or two consecutive values ě0.5 in serum as the cut-off that should
prompt further diagnostic work-up (e.g., CT-scan) for presumptive IFI [5]. Higher cut-off (single value
ě0.8 or 1.0) should be considered for BAL and CSF samples.

























Cape Cod Inc. (East
Falmouth, MA, USA)) 1
Invasive aspergillosis
Invasive candidiasis
Other invasive mycoses 2
Serum 60–80 pg/mL 5 60%–80%/80%–95%
BAL: bronchoalveolar lavage fluid, CSF: cerebrospinal fluid; 1 Other assays have been commercialized in
Japan: Fungitec-G (Seikagaku Corporation, Tokyo, Japan), Wako pure chemical industries Ltd (Tokyo, Japan),
Maruha-Nichiro foods Inc. (Tokyo, Japan); 2 With the exception of mucormycosis and cryptococcosis; 3 Based on
the cut-off of the manufacturer and experts’ recommendations; 4 The cut-off recommended by the manufacturer
is an OD 0.5. Experts recommend to consider a higher value for BAL and CSF; 5 For the Fungitell assay,
the manufacturer defines values <60 pg/mL and ě80 pg/mL as negative and positive results, respectively.
Values between 60 an 80 pg/mL are classified as indeterminate. Cut-off of the Japanese tests are different
(Fungitec-G: 20 pg/mL, Wako and Maruha tests: 11 pg/mL); 6 These ranges of values are indicative and based
on the results of different meta-analyses. These values may differ according to the patients’ population.
The diverse BDG tests detect 1,3-β-D-glucan, which is the major cell wall component of most
fungal species, with the exception of fungi of the subdivision Mucoromycotina, Cryptococcus spp. and
some other Basidiomycota (e.g., Malassezia spp.) that contain less 1,3-β-D-glucan in their cell wall and
are usually not detected by these tests. Thus, BDG assay is not specific for the diagnosis of invasive
aspergillosis and is also used for the diagnosis of invasive candidiasis. 1,3-β-D-glucan is a trigger of
innate immunity and activates the coagulation cascade in horseshoe crabs. The amoebocyte lysate of
two horseshoe crab species, Limulus polyphemus and Tachypleus tridentatus, are used for the Fungitell
assay (Associates of Cape Cod Inc., East Falmouth, MA, USA) and the Japanese kits (Fungitec-G,
Seikagaku Corporation; Wako Pure Chemicals Industries Ltd.; Maruha-Nichiro Foods Inc.; Tokyo,
Japan), respectively. Upon exposure to 1,3-β-D-glucan, factor G is activated and converts the proclotting
enzyme into active clotting enzyme. Colorimetric methods (Fungitell, Fungitec-G, Maruha test) or
turbidimetric methods (Wako test) are used for detection of a substrate of this enzyme. These different
approaches result in different cut-offs of positivity according to the test in use. The Fungitell assay is
FDA approved and widely used in USA and Europe. The cut-off recommended by the manufacturer
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is ě80 pg/mL for a positive test and <60 pg/mL for a negative test with an intermediate “grey zone”
between 60 and 80 pg/mL. Lower cut-offs (11–20 pg/mL) are recommended for the Japanese kits.
The EORTC-MSG panel has included a positive BDG test as a microbiological criterion of IFI without
recommendations regarding the cut-off or the type of test [4]. New revisions of the EORTC-MSG
definitions are ongoing to address these important questions.
3. The Performance
The performance of GM and BDG testing in serum for the diagnosis of IA has been evaluated
in multiple studies and summarized in several meta-analyses [6–11]. Important heterogeneity of
results has been observed, depending on the study design (cohort vs. case-control studies), the type of
patients populations (onco-hematological vs. other), the method of screening (monitoring or punctual
testing), the criteria used to define a positive test (cut-off of positivity, number of positive tests), and the
definition of IA (use of EORTC-MSG definitions and inclusion or not of possible IA cases).
The major conclusions of these analyses can be summarized as follows:
(1) Among high-risk patients with hematological malignancies and chemotherapy-induced
neutropenia or allogeneic HSCT, both tests have a similar performance with a limited sensitivity
(60%–80%) and a specificity ě90%.
(2) The requirement of two consecutive positive tests results in a high specificity (95%–99%),
with a slight loss of sensitivity.
(3) Insufficient data are available to assess the performance of these tests in solid-organ transplant
recipients and other populations of immunocompromised patients at low or moderate risk of IA.
However, sensitivity appears to be markedly decreased in this setting (40% or less), which can be
explained by the limited angio-invasion in patients with better immune defenses compared to
those with neutropenia. Concerns about poor specificity have also been raised, in particular for
BDG testing in lung transplant recipients in one study [12].
(4) Data among pediatric populations are also lacking. However, the performance of these tests
(especially for GM) seems to be similar to that in adults, but lower specificity has been reported
in some studies [11,13,14].
The performance of GM in BAL has been assessed in several studies and two meta-analyses
suggest an overall performance of 85% sensitivity and 90%–95% specificity [15,16]. The requirement of
a higher cut-off (OD 1.0 versus 0.5) was associated with a substantial gain in specificity (95% vs. 90%,
respectively), without loss of sensitivity. Good diagnostic accuracy of GM in BAL was also reported
in solid-organ transplant recipients (in particular lung transplant recipients) with sensitivity and
specificity comparable to those observed in hematologic cancer patients [17,18]. Combination of GM
testing with molecular methods (PCR targeting A. fumigatus or Aspergillus spp.) has been suggested for
improved performance (97% sensitivity and specificity for either GM or PCR positive) [19]. There are
no data supporting the use of BDG testing in BAL.
Both the EORTC-MSG and ECIL panels have validated GM testing in CSF for the diagnosis of
cerebral aspergillosis [4,5], which is supported by a recent study showing a sensitivity of 88% and a
specificity of 96% in this setting [20].
Multiple possible causes of false positive results have been evoked, such as concomitant
bacterial infections, β-lactam antibiotics, blood transfusions, blood-derived products, gluconate
sodium-containing products (Plasma-Lyte solution, food), and renal replacement therapy [21]. For GM,
the major concern was about the concomitant administration of piperacillin-tazobactam (a standard
antibacterial therapy of febrile neutropenia) [22]. However, new formulations of the drug have
been developed with a supposed lower risk of false positive reactivity [23,24]. For BDG, the most
important cause of false positivity that was demonstrated is concomitant continuous renal replacement
therapy [12]. Cross-reactivity with other fungi may also contribute to false positive results. Another
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important factor to consider is the high risk of contamination during the pre-analytical phase. It is
recommended to test a second aliquot of the same sample to confirm a positive GM or BDG result.
Regarding false negative results, the major factor seems to be directly linked to the pathogenesis
of IA with different degrees of angio-invasion and dissemination according to the level of
immunosuppression of the host, with a better sensitivity of both tests in onco-hematological and/or
neutropenic patients compared to solid-organ transplant recipients or other patients with less severe
immunosuppression. There is no strong evidence about the role of antifungal prophylaxis in false
negative results of GM or BDG.
The timing of GM or BDG positivity in serum in relationship with the appearance of the first
clinical or radiological signs of IA has been investigated in some studies with controversial results
depending on the screening strategy and diagnostic approach in use [25–27].
A robust set of data, including one meta-analysis, also supports the role of GM measurement in
serum in follow-up as a marker of response to therapy and predictor of IA outcomes [28–31]. A decline
of GM values within the first one or two weeks after initiation of antifungal therapy was associated
with better prognosis compared to persistently high values, and we may recommend GM testing
in follow-up at day 7 and 14 on the basis of these results [28,29]. However, BDG testing did not
demonstrate a utility in follow-up with frequent persistence of high serum levels independently of IA
outcomes [32].
4. The Clinical Utility
The diagnosis of IA relies on a constellation of clinical and paraclinical parameters, most of
which are only presumptive and do not constitute per se a proof of infection. Because of their limited
sensitivity and specificity, GM and BDG results should only be interpreted in conjunction with other
clinical, radiological and microbiological criteria of IA as defined by the EORTC-MSG consensus [4].
From this point of view, two important questions should come to mind regarding the utility of GM
and BDG testing in clinical practice. First, which patient should be tested? Second, when and how the
test should be performed (in other words, what should be the approach or strategy of screening)?
4.1. Which Patient Should Be Tested?
For a given sensitivity and specificity, the positive and negative predictive values (PPV and NPV,
respectively) will depend on the prevalence of the disease in a defined population and/or the pre-test
probability of the disease in an individual. For instance, if we consider a prevalence of IA of about
10% in a high-risk population of patients with hematologic malignancies and chemotherapy-induced
neutropenia and a sensitivity and specificity of GM or BDG around 80% and 90% respectively, the
PPV would be about 50% and NPV 97%. If the patient has concomitant radiological signs consistent
with IA (high pre-test probability), a positive result would definitely indicate an at least probable IA.
However, assuming a similar specificity in a population with a lower IA incidence (e.g., 2%–3%),
such as solid-organ transplant recipients, the PPV would fall below 20% and a positive result would
likely represent a false positive result if clinical suspicion is low or moderate. Moreover, because the
sensitivity is also decreased in this later population (as mentioned above), we cannot rely on a negative
result to exclude the disease if clinical/radiological criteria are present.
Based on these considerations, we can conclude that GM and BDG testing has a role for routine IA
diagnosis in patients with hematological malignancies during the high risk period (i.e., neutropenia or
post allogeneic HSCT). However, their value is limited in other settings, such as solid-organ transplant
recipients or non-neutropenic patients, in which IA prevalence is lower and sensitivity/specificity
of the tests is decreased. Use of GM or BDG testing in these populations should be determined on
the basis of individual assessment of the pre-test probability of IA according to host factors and
clinical signs.
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4.2. When and How the Test Should Be Performed?
We can distinguish two strategies of GM or BDG testing in serum. Punctual testing can be
performed in case of clinical suspicion of IA (e.g., abnormal radiological finding consistent with IA)
to precise the diagnosis. Alternatively, monitoring of BDG or GM can be performed in a selected
population of high-risk patients (e.g., two or three times per week among onco-hematological patients
during the neutropenic phase) in the absence of clinical signs or symptoms for early detection of IA.
In this later scenario, a positive GM or BDG testing would be the first hint of the disease and trigger
further diagnostic work-up including CT-scan and bronchoscopy. While monitoring strategies are
applied in many onco-hematology wards, few studies have assessed the real benefit of this pre-emptive
approach [33–35]. Thus, we cannot conclude that one algorithm is better than another. However,
a monitoring strategy may be justified in high-risk patients.
Another important question is the number of positive tests required to define a positive result
(i.e., one single versus two consecutive positive tests). As mentioned earlier, false positive results
are relatively frequent and any positive result should, at least, be confirmed on a second aliquot of
the same sample. In addition, most experts recommend the repetition of the test on a subsequent
serum sample, as most studies addressing this question suggest a significant increase of specificity
(from 80%–90% to ě97%) with the requirement of two consecutive positive tests in serum for the
diagnosis of proven/probable IA [7,36].
GM testing can also be performed in samples other than serum (BAL, CSF). The sensitivity and
specificity of the test in BAL are higher than those reported in serum and we recommend testing of GM
in BAL in all immunocompromised patients undergoing bronchoscopy for suspicion of pulmonary IA
on the basis of CT imaging. The cut-off is still debated, but an OD result <0.5 virtually rules out the
diagnosis, while a value ě3 has near 100% positive predictive value [37]. While cerebral aspergillosis
is a rare disease, GM testing in CSF appears as a promising diagnostic tool and can be recommended
in this setting.
GM is also useful in the follow-up for assessment of therapeutic response. While radiological
signs of improvement are often delayed and not evident before two weeks or more, a decline or
increase of GM values in serum may be the first indicator of therapeutic success or failure, respectively.
We recommend weekly monitoring of GM values during antifungal therapy of IA until values <0.5
are achieved.
5. Conclusions
Because microbiological documentation of IA is difficult to obtain, fungal biomarkers, such as
GM and BDG, are increasingly used for the presumptive diagnosis of IA. Both tests achieve detection
of IA with a comparable performance, but sensitivity and specificity are not optimal. Before requesting
GM or BDG testing, the physician should ask himself the following questions:
(1) What is the pre-test probability of IA based on the prevalence of IA in this population and the
clinical signs/symptoms of this patient?
(2) What are the positive and negative predictive values of the test in this particular case? (In other
words, how would the result impact the decision to treat or not to treat?)
In high risk patients with clinical/radiological signs of possible IA (high pre-test probability),
a positive GM or BDG would probably have little impact on therapeutic decisions as these patients
would be treated anyway (Figure 1). However, it may reinforce the diagnosis of IA (from possible to
probable), help in differentiating IA from other mycoses, and serve as a baseline for follow-up. In these
high-risk patients, GM or BDG monitoring (once or twice weekly) may also be helpful for the early
detection of IA in pre-emptive strategies.
Inversely, in patients with low pre-test probability, GM or BDG results may be difficult to interpret
and turn to be more confusing than helpful because of low positive predictive value (high risk of false
positive results) and decreased sensitivity in non-hematological populations (Figure 1).
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There is a large “in-between” or grey zone, in which GM or BDG testing may be helpful for
therapeutic decisions when interpreted in conjunction with host factors and clinical/radiological
findings on an individual basis.
Finally, it should be reminded that neither GM nor BDG are appropriate to detect mucormycosis,
the second most frequent invasive mold infection that affects the same patients’ population as IA and
has a similar clinical presentation.
In conclusion, GM or BDG testing should be targeted on the right population and right situation
to offer the optimal benefit in the approach of IA diagnosis and management.
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